Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX130 in advanced renal cell carcinoma
NCT04438083Phase 1Terminated
- Sponsor
- CRISPR Therapeutics
- Start
- Jun 2020
- Primary completion
- Oct 2024
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of CTX130 in clear cell renal cell carcinoma (ccRCC), sponsored by CRISPR Therapeutics. Primary endpoints: Incidence of adverse events at 28 days and Objective Response Rate at 60 months. Started Jun 2020; status: terminated.
02
Drugs
CTX130
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04438083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438083.